![]() | Only 14 pages are availabe for public view |
Abstract Breast cancer is one of the most common cancers among Egyptian females, where there is a 5.04% cumulative risk of developing breast cancer (Sung et al., 2021). One of the risk factors of breast cancer is the exposure to high unopposed levels of estrogen (Pike et al., 1993). One source of estrogen is its peripheral conversion from androgen to estrogen by the action of aromatase, which by turn is regulated by Fork head box L2 protein, which is a transcription factor. FOXL2 is an important factor in folliculogenesis, and its somatic mutation led to premature ovarian failure. FOXL2 gene is mutated in 97% of granulosa cell tumor of the ovary, leading to the overexpression of circulating estrogen in affected patients. Moreover, by using bioinformatic tools, we found that FOXL2 can be regulated by miR-133a and miR-133b, which are short single stranded coding non-protein RNA, imposing their effect by acting on targeted genes post-transcriptionally. In this study we aimed to assess the relationship between FOXL2, ER and PR by assessing their immunohistochemical expression and analyzing their association with different clinical and pathological factors. Furthermore, we assessed the levelsof miR-133b and miR-133a expression in comparison with benign breast conditions and normal breast tissue. We examined 68 cases of breast cancer, 33 control cases of normal breast tissue, and 26 cases showing benign breast conditions. Our sample included females and excision specimens exclusively. We found that ER was immunohistochemically expressed in 72% of cases, PR in 65% of cases and FOXL2 was expressed in 72% of cases of breast cancer tissue. Its expression in breast cancer was correlated with the pT stage of the tumor |